In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Curis (CRIS). The company’s shares closed last Monday at $8.20, close to its 52-week high of $8.66.
According to TipRanks.com, Roy is a top 100 analyst with an average return of 57.5% and a 62.2% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Actinium Pharmaceuticals, and Adaptimmune Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Curis with a $9.50 average price target, representing a 15.9% upside. In a report issued on December 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $9.00 price target.
See today’s analyst top recommended stocks >>
Based on Curis’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.74 million and GAAP net loss of $5.97 million. In comparison, last year the company earned revenue of $2.86 million and had a GAAP net loss of $6.44 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
